Rectal Cancer Therapeutic Pipeline Assessment and Review H1 2015 Market Research Report

DALLAS, March 25, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Rectal Cancer - Pipeline Review, H1 2015" therapeutic market research report of 106 pages with latest updates, data and information to its online business intelligence library.

The report "Rectal Cancer - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Rectal cancer is a disease in which malignant (cancer) cells form in the tissues of the rectum. The symptoms of rectal cancer may be similar to those of other bowel diseases, like ulcerative colitis, Crohn's disease or even colon or colorectal cancers. More than 40,000 people in the United States develop rectal cancer each year. Rectal cancer treatment often involves surgery to remove the cancer. Other treatments, such as chemotherapy and radiation therapy, may be used as well.

The report also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Companies discussed in this report include AbbVie Inc., Apogenix GmbH, Cerulean Pharma, Inc., GlaxoSmithKline plc, Hanwha Chemical Corporation, Incuron, LLC, Karyopharm Therapeutics, Inc., Nanobiotix, Peregrine Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Synta Pharmaceuticals Corp.

Drug Profiles discussed in this report include APG-350, bavituximab, CRLX-101, ganetespib, GSK-2256098, HD-204, mepacrine, NBTX-IV, NBTXR-3, selinexor, veliparib, ziv-aflibercept (recombinant). Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310122 . (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The scope of the report ranges from global therapeutic landscape of Rectal Cancer to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics

More reports on cancer therapeutics Market:

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics 

The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the thirdand fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. Complete report available at http://www.rnrmarketresearch.com/colorectal-cancer-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics-market-report.html .

Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Acute Lymphoblastic Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include EpiZyme, Inc., Juno Therapeutics Inc., Novartis AG, Zymeworks Inc. Complete report available at http://www.rnrmarketresearch.com/acute-lymphoblastic-lymphoma-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com